(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 15.76% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.47%.
Neuropace's revenue in 2026 is $98,836,000.On average, 11 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,511,029,987, with the lowest NPCE revenue forecast at $3,330,141,063, and the highest NPCE revenue forecast at $3,643,864,928. On average, 11 Wall Street analysts forecast NPCE's revenue for 2027 to be $4,282,296,424, with the lowest NPCE revenue forecast at $3,888,597,001, and the highest NPCE revenue forecast at $4,512,269,060.
In 2028, NPCE is forecast to generate $5,313,054,372 in revenue, with the lowest revenue forecast at $4,907,684,697 and the highest revenue forecast at $5,638,105,247.